Cynomolgus Monkey OX40 (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.
Cat #
Size
Price
Quantity
818901
25 ug
$145
818902
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
TNFRSF4, OX40, CD134, OX40L receptor
Species
Cynomolgus monkey
Sources
Recombinant Cynomolgus Monkey OX40 (Lue29-Ala216) with C-terminus His-tag is expressed in CHO cell.
accession number
A0A7N9CLL2
Molecular Weight
The protein has a predicted molecular weight of 21.9 kDa. Under DTT-reducing conditions, it migrates at approximately 40 kDa on SDS-PAGE.
Affinity Tag
C-His
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.